UB Paderborn / Katalog / Suche / in CDI

Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis

CPT: pharmacometrics and systems pharmacology, 2024-04, Vol.13 (4), p.599-611

2024

Link zum Volltext

Verfügbarkeit prüfen

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

Cancer chemotherapy and pharmacology, 2021-07, Vol.88 (1), p.25-37

2021

Link zum Volltext

Verfügbarkeit prüfen

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Cancer chemotherapy and pharmacology, 2022-04, Vol.89 (4), p.499-514

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

Pediatric rheumatology online journal, 2017-12, Vol.15 (1), p.86-86, Article 86

2017

Link zum Volltext

Verfügbarkeit prüfen

S197: LINKER‐MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e1610068-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Thermal analysis of the evaporation of compounds used in aromatherapy using thermogravimetry

Thermochimica acta, 2002-09, Vol.392-393, p.221-229

2002

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Use‐Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration

Clinical pharmacology in drug development, 2021-11, Vol.10 (11), p.1375-1384

2021

Link zum Volltext

Verfügbarkeit prüfen

Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations

Journal of pharmacokinetics and pharmacodynamics, 2023-12, Vol.50 (6), p.475-493

2023

Link zum Volltext

Verfügbarkeit prüfen

Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation

Clinical pharmacokinetics, 2024-04, Vol.63 (4), p.511-527

2024

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2019-05, Vol.71 (5), p.685-695

2019

Link zum Volltext

Verfügbarkeit prüfen

Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial

British journal of clinical pharmacology, 2018-06, Vol.84 (6), p.1136-1145

2018

Link zum Volltext

Verfügbarkeit prüfen

Translational PK/PD and model-informed development of JNJ-67842125, a F ab reversal agent for JNJ-64179375, a long-acting thrombin inhibitor

British journal of pharmacology, 2021-10, Vol.178 (19), p.3943-3958

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats

Biopharmaceutics & drug disposition, 2007-09, Vol.28 (6), p.263-273

2007

Link zum Volltext

Verfügbarkeit prüfen

Translational PK/PD and model‐informed development of JNJ‐67842125, a Fab reversal agent for JNJ‐64179375, a long‐acting thrombin inhibitor

British journal of pharmacology, 2021-10, Vol.178 (19), p.3943-3958

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling

Journal of pharmacokinetics and pharmacodynamics, 2007-06, Vol.34 (3), p.333-354

2007

Link zum Volltext

Verfügbarkeit prüfen

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8006-8006

2023

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

Clinical pharmacology and therapeutics, 2024-03, Vol.115 (3), p.422-439

2024

Link zum Volltext

Verfügbarkeit prüfen

P-044 Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: results from LINKER-MM1

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S58-S59

2023

Link zum Volltext

Verfügbarkeit prüfen

P-005 Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S35

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.122-122

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic Modeling of Acute and Chronic Effects of Methylprednisolone on Hepatic Urea Cycle Genes in Rats

Gene regulation and systems biology, 2008-01, Vol.2, p.117762500800200

2008

Link zum Volltext

Verfügbarkeit prüfen

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers

Clinical immunology (Orlando, Fla.), 2018-06, Vol.191, p.10-20

2018

Link zum Volltext

Verfügbarkeit prüfen

Su1917 - Pharmacokinetics and Exposure-Response of Tofacitinib in a Phase 3 Maintenance Study in Ulcerative Colitis Patients

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S595-S596

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Exposure-Response of Tofacitinib in a Phase 3 Maintenance Study in Ulcerative Colitis Patients

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S595-S596

2017

Link zum Volltext

Verfügbarkeit prüfen

Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease

Journal of clinical pharmacology, 2015-03, Vol.55 (3), p.241-250

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

S197: LINKER‐MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Thermal analysis of the evaporation of compounds used in aromatherapy using thermogravimetry

Pharmacokinetics and Use‐Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration

Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations

Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial

Translational PK/PD and model-informed development of JNJ-67842125, a F ab reversal agent for JNJ-64179375, a long-acting thrombin inhibitor

Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats

Translational PK/PD and model‐informed development of JNJ‐67842125, a Fab reversal agent for JNJ‐64179375, a long‐acting thrombin inhibitor

Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

P-044 Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: results from LINKER-MM1

P-005 Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)

Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Pharmacodynamic Modeling of Acute and Chronic Effects of Methylprednisolone on Hepatic Urea Cycle Genes in Rats

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers

Su1917 - Pharmacokinetics and Exposure-Response of Tofacitinib in a Phase 3 Maintenance Study in Ulcerative Colitis Patients

Pharmacokinetics and Exposure-Response of Tofacitinib in a Phase 3 Maintenance Study in Ulcerative Colitis Patients

Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease

Suchergebnisse filtern